Theravance Biopharma Inc
NASDAQ:TBPH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.66
11.59
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TBPH stock under the Base Case scenario is 7.81 USD. Compared to the current market price of 9.47 USD, Theravance Biopharma Inc is Overvalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Theravance Biopharma Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TBPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Theravance Biopharma Inc
Balance Sheet Decomposition
Theravance Biopharma Inc
Current Assets | 116.5m |
Cash & Short-Term Investments | 91.4m |
Receivables | 16.8m |
Other Current Assets | 8.3m |
Non-Current Assets | 239.6m |
PP&E | 37.1m |
Other Non-Current Assets | 202.5m |
Current Liabilities | 23.4m |
Accounts Payable | 1.5m |
Accrued Liabilities | 15.5m |
Other Current Liabilities | 6.5m |
Non-Current Liabilities | 147m |
Long-Term Debt | 29.7m |
Other Non-Current Liabilities | 117.3m |
Earnings Waterfall
Theravance Biopharma Inc
Revenue
|
63.2m
USD
|
Operating Expenses
|
-102.7m
USD
|
Operating Income
|
-39.5m
USD
|
Other Expenses
|
-9.9m
USD
|
Net Income
|
-49.4m
USD
|
Free Cash Flow Analysis
Theravance Biopharma Inc
USD | |
Free Cash Flow | USD |
TBPH Profitability Score
Profitability Due Diligence
Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
TBPH Solvency Score
Solvency Due Diligence
Theravance Biopharma Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Theravance Biopharma Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TBPH Price Targets Summary
Theravance Biopharma Inc
According to Wall Street analysts, the average 1-year price target for TBPH is 13.46 USD with a low forecast of 9.09 USD and a high forecast of 22.05 USD.
Dividends
Current shareholder yield for TBPH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TBPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Contact
IPO
Employees
Officers
The intrinsic value of one TBPH stock under the Base Case scenario is 7.81 USD.
Compared to the current market price of 9.47 USD, Theravance Biopharma Inc is Overvalued by 18%.